No Data
No Data
Express News | Agenus to Provide Corporate Update and First Quarter 2025 Financial Report
Press Release: Agenus to Provide Corporate Update and First Quarter 2025 Financial Report
Agenus: Initial Results From NEOASIS Show BOT/BAL Efficacy In Neoadjuvant Setting Across Multiple MSS And MSI-H Solid Tumors
Agenus Announces Botensilimab and Balstilimab Presentations at ASCO 2025
New Analyst Forecast: $AGEN Given 'Buy' Rating
B.Riley Financial Maintains Agenus(AGEN.US) With Buy Rating, Cuts Target Price to $8